Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax

NCT02322528 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Sjogren's Disease

Interventions

DRUG: Administration of Lotemax

Sponsor

University of Rochester

Collaborators

[object Object]